BioCentury
ARTICLE | Clinical News

Metadoxine ER: Phase IIb started

September 1, 2014 7:00 AM UTC

Alcobra began a double-blind, placebo-controlled, U.S. and Israeli Phase II trial to evaluate 2 dose levels of oral MDX once daily for 6 weeks in 60 patients ages 15-55 years with fragile X syndrome. ...